Search

You searched for "vestibular"

432 results found

The work of BIPOSA

4 December 2023 | EYE - Paediatrics, EYE - Strabismus
The British and Irish Paediatric Ophthalmology and Strabismus Association (BIPOSA) was set up in 2008 to merge two streams of ophthalmology, namely the practice of paediatric ophthalmology and the practice of strabismus (to include refracting in children, and strabismus in...

In conversation with Robert MacLaren

2 December 2019 | EYE - Vitreo-Retinal, EYE - General
Professor Robert MacLaren gave the Keeler Lecture at the Royal College of Ophthalmologists Annual Meeting in May 2019 on gene therapy for retinitis pigmentosa. We caught up with him afterwards to find out more. What are the key messages of...

Eyes on Rwanda: Lessons from an international ophthalmology experience

2 October 2025 | | EYE - Cataract, EYE - Glaucoma
On the 26 February 2025, I travelled to Rwanda on the invitation of a former Belfast trainee, Michael Mikhail. Michael is now one of only two vitreoretinal (VR) surgeons in Rwanda, a country with a population of 14 million. Born...

Innovations in posterior uveitis: In conversation with Dr Colin Chu

1 July 2025 | | EYE - Imaging
A research team has been awarded significant funding by the National Institute for Health and Care Research (NIHR) to develop an innovative drug-device combination that aims to revolutionise how individual immune cells are monitored and treated in patients at Moorfields...

Over one million estimated to have glaucoma in UK

5 February 2026 | glaucoma, research, patient stories
Over one million people are estimated to currently have glaucoma in the UK, a figure projected to reach more than 1.6 million by 2060, according to a study led by Moorfields and UCL researchers. The new figures, published in the...

UKISCRS Cornea & Cataract Day 2026

16 March 2026
United Kingdom & Ireland Society of Cataract & Refractce Surgeons Cornea & Cataract Day 2026

The most memorable patient encounters and what they taught me

3 April 2026 | | EYE - General
In ophthalmology, some encounters blend quietly into the rhythm of clinic. Others stay with us, shaping how we practice and who we become as clinicians. These moments become the unexpected teachers of our training. They are subtle yet leave a...

Cutting-edge practice in glaucoma care: what, how and why?

1 April 2016 | | EYE - Glaucoma
More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

Collaborating across the Caribbean to tackle diabetic retinopathy

1 December 2017 | | EYE - Vitreo-Retinal, EYE - General
The VISION 2020 LINKS Programme has been running since 2004, with a focus on improving the quality and quantity of eye care training in low-income countries [1]. In 2014, the Diabetic Retinopathy Network (DR-NET) was established [2]. This is a...

Paediatric ophthalmology training in Malawi through the Vision 2020 LINKS Programme: a decade of partnership

1 December 2016 | | EYE - Cataract, EYE - Cornea, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal, EYE - General
Blinding eye disease in children can lead to a lifetime of dependence and non-productivity for the person afflicted. Sometimes a relatively simple condition such as a refractive error can lead to irreversible disability that could, if caught in time, have...

Principles of management

1 August 2016 | | EYE - Cataract, EYE - Cornea, EYE - Pathology
Whatever section of pathology is to blame and wherever it strikes, the aim of treatment is always the same. Find the cause if you can. Establish the effects of the cause. Halt the pathological process if you can. Reverse its...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

1 April 2016 | | EYE - General
The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...